HK1051369A1 - Multicyclic compounds and their use as inhibitors of parp, begfr2 and mlk3 enzymes - Google Patents
Multicyclic compounds and their use as inhibitors of parp, begfr2 and mlk3 enzymesInfo
- Publication number
- HK1051369A1 HK1051369A1 HK03103639A HK03103639A HK1051369A1 HK 1051369 A1 HK1051369 A1 HK 1051369A1 HK 03103639 A HK03103639 A HK 03103639A HK 03103639 A HK03103639 A HK 03103639A HK 1051369 A1 HK1051369 A1 HK 1051369A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- parp
- begfr2
- inhibitors
- mlk3
- enzymes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20294700P | 2000-05-09 | 2000-05-09 | |
US09/850,858 US7122679B2 (en) | 2000-05-09 | 2001-05-08 | Multicyclic compounds and the use thereof |
PCT/US2001/014996 WO2001085686A2 (fr) | 2000-05-09 | 2001-05-09 | Nouveaux composes multicycliques et leur utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1051369A1 true HK1051369A1 (en) | 2003-08-01 |
Family
ID=26898160
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03103639A HK1051369A1 (en) | 2000-05-09 | 2003-05-22 | Multicyclic compounds and their use as inhibitors of parp, begfr2 and mlk3 enzymes |
HK07104126.2A HK1097841A1 (en) | 2000-05-09 | 2007-04-19 | Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes |
HK09107488.5A HK1129381A1 (en) | 2000-05-09 | 2009-08-14 | Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07104126.2A HK1097841A1 (en) | 2000-05-09 | 2007-04-19 | Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes |
HK09107488.5A HK1129381A1 (en) | 2000-05-09 | 2009-08-14 | Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes |
Country Status (28)
Country | Link |
---|---|
US (1) | US7122679B2 (fr) |
EP (3) | EP1754707B1 (fr) |
JP (1) | JP5156150B2 (fr) |
KR (1) | KR100832602B1 (fr) |
CN (2) | CN101560213B (fr) |
AT (3) | ATE482215T1 (fr) |
AU (1) | AU6132701A (fr) |
BG (1) | BG66036B1 (fr) |
BR (1) | BR0110993A (fr) |
CA (1) | CA2409758A1 (fr) |
CY (1) | CY1108722T1 (fr) |
CZ (2) | CZ305350B6 (fr) |
DE (3) | DE60136305D1 (fr) |
DK (1) | DK1754707T3 (fr) |
EA (1) | EA007868B1 (fr) |
ES (2) | ES2256238T3 (fr) |
HK (3) | HK1051369A1 (fr) |
HU (1) | HU229448B1 (fr) |
IL (1) | IL152663A0 (fr) |
MX (1) | MXPA02010977A (fr) |
NO (1) | NO324256B1 (fr) |
NZ (1) | NZ522539A (fr) |
PL (1) | PL226805B1 (fr) |
PT (1) | PT1754707E (fr) |
SK (1) | SK287591B6 (fr) |
UA (1) | UA73773C2 (fr) |
WO (1) | WO2001085686A2 (fr) |
ZA (1) | ZA200209065B (fr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811992B1 (en) * | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
US20060276497A1 (en) * | 2000-05-09 | 2006-12-07 | Cephalon, Inc. | Novel multicyclic compounds and the use thereof |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
AU2002354499A1 (en) * | 2001-12-18 | 2003-06-30 | Kyowa Hakko Kogyo Co., Ltd. | Indole derivative |
WO2003091255A1 (fr) * | 2002-04-26 | 2003-11-06 | Warner-Lambert Company Llc | Inhibiteurs de checkpoint kinases (wee1 et chk1) |
US7094798B1 (en) | 2002-04-26 | 2006-08-22 | Pfizer Inc | Inhibitors of checkpoint kinases (Wee1 and Chk1) |
AU2003229953A1 (en) | 2002-04-30 | 2003-11-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7511065B2 (en) | 2003-11-12 | 2009-03-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
DK1684736T3 (da) * | 2003-12-01 | 2011-11-21 | Kudos Pharm Ltd | Inhibitorer af DNA-skadereparation til behandling af cancer |
CN1905864B (zh) * | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
AU2005243240B2 (en) * | 2004-05-03 | 2012-03-15 | Janssen Pharmaceutica N.V. | Novel indole derivatives as selective androgen receptor modulators (SARMS) |
AU2006206512B2 (en) | 2005-01-19 | 2012-09-13 | Eisai Inc. | Diazabenzo(de)anthracen-3-one compounds and methods for inhibiting PARP |
CN101242822B (zh) * | 2005-07-18 | 2011-08-24 | 彼帕科学公司 | 治疗卵巢癌的药物 |
KR101019363B1 (ko) * | 2005-09-02 | 2011-03-07 | 오츠카 세이야쿠 가부시키가이샤 | 벤즈아제핀 화합물 또는 그의 염의 제조 방법 |
JP5227796B2 (ja) * | 2005-09-29 | 2013-07-03 | アボット・ラボラトリーズ | 2位においてフェニルによって置換された1h−ベンズイミダゾール−4−カルボキサミドは強力なparp阻害薬である |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
CN101534836B (zh) * | 2006-09-05 | 2011-09-28 | 彼帕科学公司 | Parp抑制剂在制备治疗肥胖症的药物中的用途 |
JP2010502730A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ,インコーポレイティド | 癌の治療法 |
EP2059802A4 (fr) * | 2006-09-05 | 2010-09-08 | Bipar Sciences Inc | Procedes de conception d'inhibiteurs de parp et leurs utilisations |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
CL2007003331A1 (es) * | 2006-11-20 | 2008-07-04 | Cephalon Inc | Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente. |
CA2693694A1 (fr) * | 2007-06-08 | 2008-12-11 | University Of Massachusetts | Kinases de lignee mixte et troubles metaboliques |
AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
EP2842956A1 (fr) | 2007-10-03 | 2015-03-04 | Eisai Inc. | Composés inhibiteurs de la PARP, compositions et procédés d'utilisation |
WO2009051815A1 (fr) * | 2007-10-19 | 2009-04-23 | Bipar Sciences, Inc. | Procédés et compositions pour le traitement du cancer au moyen d'inhibiteurs de parp de type benzopyrone |
WO2009064738A2 (fr) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Traitement de cancer du sein avec un inhibiteur parp seul ou en combinaison avec des agents anti-tumoraux |
US20090123419A1 (en) * | 2007-11-12 | 2009-05-14 | Bipar Sciences | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
WO2009073869A1 (fr) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Traitement du cancer avec des combinaisons d'inhibiteurs de topoïsomérase et d'inhibiteurs de parp |
UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
US20090275608A1 (en) * | 2008-02-04 | 2009-11-05 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
JP2010006717A (ja) * | 2008-06-24 | 2010-01-14 | Kyorin Pharmaceut Co Ltd | ジヒドロチエノ[2,3−e]インダゾール化合物 |
LT2346495T (lt) | 2008-10-07 | 2016-10-10 | Astrazeneca Uk Limited | Farmacinė kompozicija 514 |
WO2010082813A1 (fr) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Procédé de traitement du cancer |
BR112012004053A2 (pt) * | 2009-08-26 | 2020-12-08 | Cephalon Inc | Forma cristalina de composto i, processo preparar uma forma cristalina de composto i, composto farmaceutica e processo a preparação de composto |
WO2011058367A2 (fr) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase |
WO2011077502A1 (fr) * | 2009-12-21 | 2011-06-30 | 杏林製薬株式会社 | Composé de dihydrothiéno[2,3-e]indazole |
KR101528688B1 (ko) | 2010-12-02 | 2015-06-12 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | 헤테로사이클릭 유도체, 이의 제조 방법 및 이의 의학적 용도 |
US9771325B2 (en) | 2014-02-14 | 2017-09-26 | Council Of Scientific & Industrial Research | Tricyclic compounds and preparation thereof |
WO2015121876A1 (fr) * | 2014-02-14 | 2015-08-20 | Council Of Scientific & Industrial Research | Nouveaux composés tricycliques et leur procédé de préparation |
CA2967828A1 (fr) | 2014-11-26 | 2016-06-02 | Cephalon, Inc. | Formes cristallines d'inhibiteurs de parp |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
KR101896567B1 (ko) | 2015-07-23 | 2018-09-07 | 인스티튜트 큐리 | 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도 |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
WO2017156350A1 (fr) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Méthodes de traitement du cancer |
US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
MA46779A (fr) | 2016-11-02 | 2019-09-11 | Health Research Inc | Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp |
WO2018162439A1 (fr) | 2017-03-08 | 2018-09-13 | Onxeo | Nouveau biomarqueur prédictif de la sensibilité à un traitement du cancer avec une molécule dbait |
EP3615026B1 (fr) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | Un inhibiteur de parp en combinaison avec un glucocorticoïde et/ou de l'acide ascorbique et/ou un facteur de croissance de protéines pour traiter des troubles de la cicatrisation de plaies |
US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
WO2019195658A1 (fr) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Niveaux sting comme biomarqueur pour l'immunothérapie du cancer |
WO2021041532A1 (fr) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Utilisation d'héparine pour favoriser la signalisation de l'interféron de type 1 |
GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
CN110862396B (zh) * | 2019-11-29 | 2021-06-04 | 浙江工业大学 | 一种吡咯并[3,4-c]咔唑-1,3(2H,6H)-二酮类化合物的合成方法 |
KR102572704B1 (ko) | 2019-12-16 | 2023-08-30 | 한국화학연구원 | 신규한 피리미딘 유도체 및 이의 용도 |
WO2021125803A1 (fr) | 2019-12-16 | 2021-06-24 | 한국화학연구원 | Nouveau dérivé de pyrimidine et utilisation correspondante |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
CN113636970B (zh) * | 2021-09-13 | 2023-05-23 | 河北康泰药业有限公司 | 一种异吲哚酮的化合物、制备方法及其应用 |
KR20230155351A (ko) | 2022-05-03 | 2023-11-10 | 한국화학연구원 | 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
DE3833008A1 (de) * | 1988-09-29 | 1990-04-05 | Goedecke Ag | Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US5166204A (en) * | 1989-11-01 | 1992-11-24 | Toyama Chemical Co., Ltd. | Isoindole derivatives and salts thereof and antitumor agent comprising the same |
JP3025536B2 (ja) | 1990-12-27 | 2000-03-27 | 富山化学工業株式会社 | 新規なカルバゾール誘導体およびその塩 |
CA2104873C (fr) | 1991-02-26 | 2000-05-23 | James N. Campbell | Compositions et methodes pour le traitement de la douleur entretenue par le systeme sympathique |
US5298506A (en) * | 1992-05-08 | 1994-03-29 | Brigham And Women's Hospital | Use of guanylate cyclase inhibitors in the treatment of shock |
DE4217964A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
GB9319297D0 (en) * | 1993-09-17 | 1993-11-03 | Wellcome Found | Indole derivatives |
US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
AU1911095A (en) * | 1994-02-18 | 1995-09-04 | Cephalon, Inc. | Aqueous indolocarbazole solutions |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
DE69505470T2 (de) * | 1994-08-04 | 1999-05-12 | F. Hoffmann-La Roche Ag, Basel | Pyrrolocarbazol |
US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US5728709A (en) * | 1995-03-09 | 1998-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Alkyl and aralkyl-substituted pyrrolocarbazole derivatives that stimulate platelet production |
HUP9903931A3 (en) * | 1996-08-22 | 2000-09-28 | Bristol Myers Squibb Co Wallin | Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles |
WO1998009967A1 (fr) | 1996-09-09 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Derives de pyrrolocarbazole |
WO1999008680A1 (fr) | 1997-08-15 | 1999-02-25 | The Johns Hopkins University | Procede d'utilisation d'inhibiteurs selectifs de parp pour prevenir ou traiter la neurotoxicite |
US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
WO1999011622A1 (fr) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Composes aminosubstitues, et procedes et compositions permettant d'inhiber l'activite de la parp |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
WO1999011644A1 (fr) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Composes di-n-heterocycliques, et procedes et compositions permettant d'inhiber l'activite de la parp |
US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
KR20010040939A (ko) | 1998-02-12 | 2001-05-15 | 몰레큐메틱스 리미티드 | β-시트 미메틱 및 이의 사용과 관련된 방법 |
EP1070068B2 (fr) | 1998-03-13 | 2007-01-17 | The University Of British Columbia | Derives de granulatimide utilises dans le traitement du cancer |
AU9297998A (en) | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
EP1077946A1 (fr) | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Composes condenses tricycliques inhibant l'activite de type poly(adp-ribose) polymerase (parp) |
US6063803A (en) * | 1998-06-16 | 2000-05-16 | Ortho-Mcneil Pharmaceutical, Inc. | Octahydropyrrolo-[3,4-c]carbazoles useful as analgesic agents |
CN1206535C (zh) * | 1998-08-26 | 2005-06-15 | 赛福伦公司 | 调节多谱系激酶蛋白 |
US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
-
2001
- 2001-05-08 US US09/850,858 patent/US7122679B2/en not_active Expired - Lifetime
- 2001-05-09 AT AT08075834T patent/ATE482215T1/de not_active IP Right Cessation
- 2001-05-09 ES ES01935215T patent/ES2256238T3/es not_active Expired - Lifetime
- 2001-05-09 CA CA002409758A patent/CA2409758A1/fr not_active Abandoned
- 2001-05-09 DK DK05076862T patent/DK1754707T3/da active
- 2001-05-09 EP EP05076862A patent/EP1754707B1/fr not_active Expired - Lifetime
- 2001-05-09 AU AU6132701A patent/AU6132701A/xx active Pending
- 2001-05-09 WO PCT/US2001/014996 patent/WO2001085686A2/fr active Application Filing
- 2001-05-09 KR KR1020027015062A patent/KR100832602B1/ko not_active IP Right Cessation
- 2001-05-09 EA EA200201183A patent/EA007868B1/ru not_active IP Right Cessation
- 2001-05-09 DE DE60136305T patent/DE60136305D1/de not_active Expired - Lifetime
- 2001-05-09 EP EP01935215A patent/EP1294725B1/fr not_active Expired - Lifetime
- 2001-05-09 DE DE60116485T patent/DE60116485T2/de not_active Expired - Lifetime
- 2001-05-09 JP JP2001582287A patent/JP5156150B2/ja not_active Expired - Fee Related
- 2001-05-09 BR BR0110993-6A patent/BR0110993A/pt active Search and Examination
- 2001-05-09 DE DE60143140T patent/DE60143140D1/de not_active Expired - Lifetime
- 2001-05-09 CN CN2009101354977A patent/CN101560213B/zh not_active Expired - Fee Related
- 2001-05-09 HU HU0302385A patent/HU229448B1/hu not_active IP Right Cessation
- 2001-05-09 IL IL15266301A patent/IL152663A0/xx not_active IP Right Cessation
- 2001-05-09 ES ES05076862T patent/ES2315789T3/es not_active Expired - Lifetime
- 2001-05-09 MX MXPA02010977A patent/MXPA02010977A/es active IP Right Grant
- 2001-05-09 AT AT05076862T patent/ATE411997T1/de active
- 2001-05-09 CZ CZ2011-756A patent/CZ305350B6/cs not_active IP Right Cessation
- 2001-05-09 EP EP08075834A patent/EP2050750B1/fr not_active Expired - Lifetime
- 2001-05-09 SK SK1580-2002A patent/SK287591B6/sk not_active IP Right Cessation
- 2001-05-09 PL PL363167A patent/PL226805B1/pl unknown
- 2001-05-09 NZ NZ522539A patent/NZ522539A/en not_active IP Right Cessation
- 2001-05-09 PT PT05076862T patent/PT1754707E/pt unknown
- 2001-05-09 AT AT01935215T patent/ATE315039T1/de active
- 2001-05-09 CZ CZ2002-3679A patent/CZ304911B6/cs not_active IP Right Cessation
- 2001-05-09 CN CNB018120695A patent/CN100554268C/zh not_active Expired - Fee Related
- 2001-09-05 UA UA2002129794A patent/UA73773C2/uk unknown
-
2002
- 2002-11-07 ZA ZA200209065A patent/ZA200209065B/en unknown
- 2002-11-08 NO NO20025376A patent/NO324256B1/no not_active IP Right Cessation
- 2002-12-05 BG BG107355A patent/BG66036B1/bg unknown
-
2003
- 2003-05-22 HK HK03103639A patent/HK1051369A1/xx not_active IP Right Cessation
-
2007
- 2007-04-19 HK HK07104126.2A patent/HK1097841A1/xx not_active IP Right Cessation
-
2009
- 2009-01-16 CY CY20091100056T patent/CY1108722T1/el unknown
- 2009-08-14 HK HK09107488.5A patent/HK1129381A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1097841A1 (en) | Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes | |
WO2007149451A3 (fr) | Nouveaux composés multicycliques et leur utilisation | |
MY135766A (en) | Quinolinones and naphthyridinones for treating inflammatory diseases | |
WO2004093803A3 (fr) | Composes photochimiotherapeutiques utilises dans le traitement d'etats associes a pin1 | |
ATE357272T1 (de) | Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten | |
IL139826A0 (en) | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE | |
WO2000038717A3 (fr) | Techniques permettant d'utiliser un inhibiteur matriciel de la metalloproteinase et la radiotherapie comme therapie combinee pour traiter les maladies neoplasiques | |
MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
CY1109551T1 (el) | Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων | |
PT1363910E (pt) | Metodos para o tratamento de estados patologicos associados as cinases p38 e compostos de pirrolotriazina uteis como inibidores de cinases | |
WO2005016946A3 (fr) | Complexes de platine et procedes d'utilisation | |
EA200870048A1 (ru) | ГЕТЕРОАРИЛ-ЗЕМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
PL1776349T3 (pl) | Pochodne 2-amino-chinazoliny użyteczne jako inhibitory beta-sekretazy (BACE) | |
WO2005016859A3 (fr) | Inhibiteurs de proteasome et methodes les utilisant | |
WO2003032916A3 (fr) | Organosulfures inhibiteurs de tyrosine phosphatases | |
MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. | |
TR200103125T2 (tr) | Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri. | |
ATE206052T1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
ATE295724T1 (de) | Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse | |
DE60133563D1 (de) | Külen | |
NO20030762L (no) | Forbedret spesifisitet i behandling av sykdommer | |
PT1169054E (pt) | Produtos e metodos para tratar doencas relacionadas com ptp lar | |
UA64813C2 (uk) | Інтраназальний антисептик |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190509 |